# Study to Evaluate the Efficacy and Safety of Ponesimod (VSP-128) in Patients With Moderately to Severely Active Ulcerative Colitis

> **NCT07686081** · PHASE3 · RECRUITING · sponsor: **Vanda Pharmaceuticals** · enrollment: 150 (estimated)

## Conditions studied

- Ulcerative Colitis (UC)

## Interventions

- **DRUG:** Ponesimod
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07686081
- **Lead sponsor:** Vanda Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-09
- **Primary completion:** 2029-04
- **Final completion:** 2029-08
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2026-08-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07686081

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07686081, "Study to Evaluate the Efficacy and Safety of Ponesimod (VSP-128) in Patients With Moderately to Severely Active Ulcerative Colitis". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07686081. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*